RVNC — Revance Therapeutics Share News
0.000.00%
Last trade - 00:00- $379.98m
- $637.94m
- $234.04m
Brief: U.S. FDA Approves First Therapeutic Indication For Revance's DAXXIFY For Injection For Treatment Of Cervical Dystonia In Adults
Revance Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Revance Therapeutics Q2 EPS USD -0.8
Revance Therapeutics Inc expected to post a loss of 78 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Integral Ad Science Holding, Paratek Pharmaceuticals, Veru
Revance Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Revance Therapeutics Q1 product revenue USD 45.658 million
Brief: Revance Reports First Quarter 2023 Financial Results, Provides Corporate Update
Revance Therapeutics Inc expected to post a loss of 70 cents a share - Earnings Preview
Brief: FDA Approved Revance Therapeutics's Prior-Approval Supplement For Ajinomoto Althaea Doing Business As Ajinomoto Bio-Pharma Services
U.S. RESEARCH ROUNDUP-Freeport-Mcmoran, Harley-Davidson, Varonis Systems
Revance Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Revance Reports Fourth Quarter And Full Year 2022 Financial Results, Provides Corporate Update
Brief: Revance Therapeutics Q4 product revenue USD 45.73 million
Revance Therapeutics Inc expected to post a loss of 95 cents a share - Earnings Preview
Revance surges on strong demand for its anti-wrinkle injection
Brief: Revance Provides An Update On Daxxify Commercial Launch
Brief: Revance Announces U.S. FDA Acceptance Of Supplemental Biologics License Application (Sbla) For Daxxify® (Daxibotulinumtoxina-Lanm) For Injection For The Treatment Of Cervical Dystonia
Brief: Nanostics Announces New Member Of Board Of Directors